Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost to facilitate the trial and has full commercial rights There are approximately 130,000 kidney transplants around the world each year. Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis. Currently, lifelong immune suppressive therapy is required in renal transplant patients to reduce the risk of rejection. This can lead to increased risk of infections and cancer and the main anti-rejection drugs are also directly toxic to the kidneys In previous clinical trials, mesenchymal stromal/stem cells have shown potential to enable the early withdrawal of anti-rejection drugs in renal transplant recipients without increased rejection and wi
SINGAPORE, Nov. 4, 2022 /PRNewswire/ ThitsaWorks, in partnership with INFITX (previously ModusBox) and Visa, was awarded the Monetary Authority of Singapore's Financial Sector Technology and Innovation (FSTI) Proof of Concept (POC) grant on 29-June-2022. The FSTI POC grant supports the experimentation, development, and dissemination of nascent innovative technologies in the financial services sector. While many remittance options exist for overseas migrant workers in Singapore, options to reach rural areas where many workers' families live are complicated, expensive, and slow. Additionally, friends and family who only have accounts with MFIs and rural banks cannot receive direct payments. Together with Rapyd and Lucy, ThitsaWorks, INFITX, and Visa have introduced the Inclusive Cross-Border Remittances Project to make remittances for Singapore-to-Philippines corridor more affordable and efficient. The project aims to connect small financial institutions to real-time payment net